68 related articles for article (PubMed ID: 16496742)
1. [Significance of non-organ-specific autoantibodies in HCV-related chronic hepatitis].
Guidi M; Muratori P; Granito A; Muratori L; Pappas G; Bianchi FB
Recenti Prog Med; 2005 Dec; 96(12):589-93. PubMed ID: 16496742
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
Muratori P; Muratori L; Guidi M; Granito A; Susca M; Lenzi M; Bianchi FB
Clin Infect Dis; 2005 Feb; 40(4):501-7. PubMed ID: 15712070
[TBL] [Abstract][Full Text] [Related]
3. The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.
Monti V; Aghemo A; Rumi MG; Donato MF; Del Ninno E; Colombo M
Antivir Ther; 2005; 10(6):715-20. PubMed ID: 16218170
[TBL] [Abstract][Full Text] [Related]
4. Non-organ-specific autoantibodies in hepatitis C virus infection: do they matter?
Bogdanos DP; Mieli-Vergani G; Vergani D
Clin Infect Dis; 2005 Feb; 40(4):508-10. PubMed ID: 15712071
[No Abstract] [Full Text] [Related]
5. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.
Wasmuth HE; Stolte C; Geier A; Dietrich CG; Gartung C; Lorenzen J; Matern S; Lammert F
BMC Infect Dis; 2004 Feb; 4():4. PubMed ID: 15040810
[TBL] [Abstract][Full Text] [Related]
6. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
Pár A
Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
[TBL] [Abstract][Full Text] [Related]
7. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
8. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
9. Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome.
Mauss S; Berger F; Schober A; Moog G; Heyne R; John C; Pape S; Hueppe D; Pfeiffer-Vornkahl H; Alshuth U
J Viral Hepat; 2013 Apr; 20(4):e72-7. PubMed ID: 23490392
[TBL] [Abstract][Full Text] [Related]
10. [Interferons alpha in the treatment of chronic HCV infections].
Halota W; Pawłowska M; Andrejczyn M
Przegl Epidemiol; 2004; 58(3):405-11. PubMed ID: 15730004
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
12. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Horváth G; Tolvaj G; Halász T; Stotz G
Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C.
Ferri S; Muratori L; Quarneti C; Muratori P; Menichella R; Pappas G; Granito A; Ballardini G; Bianchi FB; Lenzi M
J Hepatol; 2009 Jun; 50(6):1093-101. PubMed ID: 19398235
[TBL] [Abstract][Full Text] [Related]
14. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
Wedemeyer H; Cornberg M; Manns MP
Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
[No Abstract] [Full Text] [Related]
15. Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
Marquez-Azalgara V; Hussaini T; Erb SR; Yoshida EM
Ann Hepatol; 2014; 13(5):565-7. PubMed ID: 25152991
[TBL] [Abstract][Full Text] [Related]
16. Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.
Itose I; Kanto T; Inoue M; Miyazaki M; Miyatake H; Sakakibara M; Yakushijin T; Oze T; Hiramatsu N; Takehara T; Kasahara A; Katayama K; Kato M; Hayashi N
J Med Virol; 2007 May; 79(5):511-21. PubMed ID: 17385691
[TBL] [Abstract][Full Text] [Related]
17. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
18. PEG-IFN, RBV dosing during chronic HCV re-treatment.
Highleyman L
IAPAC Mon; 2007 Feb; 13(2):55. PubMed ID: 17948601
[No Abstract] [Full Text] [Related]
19. Therapy of hepatitis C: from empiricism to eradication.
Pawlotsky JM
Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
Bräu N
Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
